EntryPoint Capital LLC Makes New $275,000 Investment in Personalis, Inc. (NASDAQ:PSNL)

EntryPoint Capital LLC purchased a new stake in Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 47,513 shares of the company’s stock, valued at approximately $275,000. EntryPoint Capital LLC owned approximately 0.07% of Personalis as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock valued at $2,683,000 after purchasing an additional 83,068 shares during the period. abrdn plc bought a new stake in Personalis during the fourth quarter valued at $1,722,000. State Street Corp grew its position in Personalis by 34.5% during the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after buying an additional 44,900 shares in the last quarter. Walleye Capital LLC bought a new position in Personalis in the 3rd quarter worth about $897,000. Finally, Jane Street Group LLC raised its holdings in shares of Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after acquiring an additional 99,671 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Lake Street Capital upped their price objective on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Needham & Company LLC lowered their price objective on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Personalis in a report on Friday, February 28th. Finally, Craig Hallum started coverage on shares of Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $7.80.

Personalis Price Performance

NASDAQ PSNL opened at $3.62 on Friday. The stock has a market capitalization of $319.51 million, a PE ratio of -2.15 and a beta of 1.73. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The business’s 50-day moving average is $4.60 and its 200 day moving average is $4.80.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $16.80 million for the quarter, compared to analyst estimates of $15.48 million. As a group, equities research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.